Modified vaccinia ankara
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Modified vaccinia ankara
- DrugBank Accession Number
- DB15483
- Background
Not Available
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Modified Vaccinia Virus (Ankara-Bavarian Nordic)
- MVA
- MVA-BN
- Vaccinia strain modified ankara
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Imvamune Suspension 50000000 CCID50 / 0.5 mL Subcutaneous Bavarian Nordic As 2015-06-15 Not applicable Canada 
Imvanex Injection, suspension 50000000 Inf. U Subcutaneous Bavarian Nordic A/S 2020-12-18 Not applicable EU 
Mvabea Injection, suspension 70000000 Inf. U Intramuscular Janssen Cilag International Nv 2021-02-11 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- JDS6958QAG
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Subcutaneous 50000000 CCID50 / 0.5 mL Injection, suspension Subcutaneous 50000000 U.inf. Injection, suspension Subcutaneous 50000000 Inf. U Injection, suspension Intramuscular 0.5 ML Injection, suspension Intramuscular 70000000 Inf. U - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on August 30, 2019 17:59 / Updated on October 24, 2021 16:00